Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 102

Results For "medicines"

1416 News Found

GlycoEra AG appoints Tanmoy Ganguly as Chief Scientific Officer
People | June 17, 2022

GlycoEra AG appoints Tanmoy Ganguly as Chief Scientific Officer

Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics


LG Chem’s new drug for obesity receives additional orphan drug designation by US FDA
News | June 16, 2022

LG Chem’s new drug for obesity receives additional orphan drug designation by US FDA

With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development


Dr. Reddy's Lab launches sorafenib tablets in US
News | June 15, 2022

Dr. Reddy's Lab launches sorafenib tablets in US

Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.


ProBioGen  and ValenzaBio enter second service agreement
Biotech | June 15, 2022

ProBioGen and ValenzaBio enter second service agreement

The new program includes upstream and downstream process development and large-scale GMP production.


CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
News | June 15, 2022

CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics

The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics


CCI approves acquisition of corporate restructuring of GlaxoSmithKline Consumer Healthcare
News | June 15, 2022

CCI approves acquisition of corporate restructuring of GlaxoSmithKline Consumer Healthcare

The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger


Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma
News | June 14, 2022

Nuvectis announces positive data for NXP900 in a preclinical model of Group 4 medulloblastoma

Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease


Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo
News | June 12, 2022

Quizartinib Plus chemotherapy significantly improved overall survival compared to chemo

Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium


China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Drug Approval | June 12, 2022

China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer

Tislelizumab is now approved in nine indications in China


Sanofi Dupixent gets USFDA nod for atopic dermatitis
Drug Approval | June 10, 2022

Sanofi Dupixent gets USFDA nod for atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood